What we are watching
Top 10 by severity and recency
Reimbursement watchlist
The dialysis-to-home transition is reshaping the renal economics base.
Coverage and formulary decisions on SGLT2 inhibitors with cardiorenal indications, Kerendia for diabetic kidney disease, and the CMS End-Stage Renal Disease Treatment Choices (ETC) model are in active rewrite. Value-based kidney care arrangements at DaVita, Fresenius, and integrated providers are repricing the dialysis floor. AimwellBio's CMS LCD ingest is in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as the indexer comes online.
Saudi Arabia · Vision 2030
Vision 2030 nephrology capacity is in active buildout. The procurement window crosses dialysis, transplant, and diabetic kidney disease.
The GCC and MENA cluster represents the highest-density sovereign-procurement opportunity for AimwellBio's renal intelligence layer. SFDA approvals, MOH formulary movements, dialysis capacity expansion, transplant program disclosures, and cross-border clinical infrastructure across Riyadh, Abu Dhabi, and Amman are already trackable through the indication-aware pipeline.
Decisions of this scale — coverage policy, dialysis-modality procurement, transplant network expansion, and SGLT2 / Kerendia formulary placement — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal.
Monitored issuers and operators
Volume & cadence of public disclosure
Methodology
This report is generated from a live ingest pipeline (tools/scout-ingest). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated —. Every signal carries source URL and fetch timestamp; click any card to view origin.
Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.
Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged companies (KSA, GCC, MENA) reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.